Skip to main content

Advertisement

Log in

Low investigation rate for adrenal incidentalomas

  • Research Letter
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

The prevalence of adrenal incidentaloma has increased with the increasing use of imaging techniques. While majority are benign adenoma, a small but significant minority may be primary adrenal carcinoma or have endocrine hyper secretion. Existing guidance suggests that excess catecholamine and cortisol secretion should be ruled out in all cases and excess aldosterone secretion should be ruled out in hypertensive patients. Repeat evaluation after a period of time is also suggested. We have reviewed the management of adrenal incidentaloma in a large district general hospital in the North West of England.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. G. Mansmann et al., The clinically inapparent adrenal mass: update in diagnosis and management. Endocr. Rev. 25(2), 309–340 (2004)

    Article  PubMed  Google Scholar 

  2. L. Hammarstedt et al., Adrenal Study Group of Western Sweden. Adrenal lesion frequency: a prospective, cross-sectional CT study in a defined region, including systematic re-evaluation. Acta Radiol. 51(10), 1149–1156 (2010)

    Article  PubMed  Google Scholar 

  3. T.J. Cawood et al., Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur. J. Endocrinol. 161(4), 513–527 (2009)

    Article  PubMed  CAS  Google Scholar 

  4. W.F. Young Jr., The incidentally discovered adrenal mass. N. Engl. J. Med. 356, 601–610 (2007)

    Article  PubMed  CAS  Google Scholar 

  5. I. Chiodini et al., Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J. Clin. Endocrinol. Metab. 95(6), 2736–2745 (2010)

    Article  PubMed  CAS  Google Scholar 

  6. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”). NIH Consens. State Sci. Statements. 19(2), 1–25 (2002)

  7. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations

  8. M.A. Zeiger et al., American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations. Endocr Pract 15(5), 450–453 (2009)

    PubMed  Google Scholar 

  9. L.K. Nieman, Approach to the patient with an adrenal incidentaloma. J. Clin. Endocrinol. Metab. 95(9), 4106–4113 (2010)

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. Bujawansa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bujawansa, S., Bowen-Jones, D. Low investigation rate for adrenal incidentalomas. Endocrine 40, 134–136 (2011). https://doi.org/10.1007/s12020-011-9487-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-011-9487-9

Keywords

Navigation